Skip to content
2000
Volume 2, Issue 1
  • ISSN: 2666-0016
  • E-ISSN: 2666-0008

Abstract

A simple, rapid, precise and accurate RP-HPLC stability indicating method was developed and validated for the estimation of Febuxostat in bulk drug and marketed tablet formulation.

The chromatographic separation was achieved on Agilent C18 (250 x 4.6 mm, 5 µm) using solvent 15 mM ammonium acetate buffer (pH 4.8) and acetonitrile (30:70 v/v) as a mobile phase at flow rate of 1 mL/min and ambient column temperature analysis were carried out at detection wavelength of 315 nm.

The method was validated for linearity, precision, accuracy, specificity, LOD and LOQ, and robustness. The linearity was studied in the concentration range of 5-25 µg/mL and correlation coefficient was found to be 0.999. The limit of detection and the limit of quantitation were found to be 0.37 µg/mL and 1.13 µg/mL. Febuxostat was subjected to stress conditions of degradation, including acidic, alkaline, oxidation, photolytic and thermal degradation. Febuxostat is more sensitive toward acidic condition than oxidation and less sensitive towards alkaline, thermal and photolytic degradation.

The method is simple, reliable, sensitive and precise, which could separate the drug and their degraded product formed under various stress conditions; thus it can be employed as stability-indicating method for the determination of FBX in bulk and pharmaceutical dosage form.

Loading

Article metrics loading...

/content/journals/ccchem/10.2174/2666001601666210427114547
2021-04-27
2025-03-16
Loading full text...

Full text loading...

References

  1. StampL.K. O’DonnellJ.L. ChapmanP.T. Emerging therapies in the long-term management of hyperuricaemia and gout.Intern. Med. J.200737425826610.1111/j.1445‑5994.2007.01315.x 17388867
    [Google Scholar]
  2. LoveB.L. BarronsR. VeverkaA. SniderK.M. Urate-lowering therapy for gout: Focus on febuxostat.Pharmacotherapy201030659460810.1592/phco.30.6.594 20500048
    [Google Scholar]
  3. JamesE. Febuxostat: A Review of its use in the treatment of Hyperuricaemia in patient with Gout.Aids Drug Evaluation2015754427438
    [Google Scholar]
  4. MusirikeM.R. Hussain ReddyK. MalluU.R. Development and validation of reverse phase-ultra performance liquid chromatographic method for estimation of related substances in febuxostat drug substance.Pharm. Anal. Acta2015643110.4172/2153‑2435.1000431
    [Google Scholar]
  5. KadivarM.H. SinhaP.K. KushwahD. JanaP. SharmaH. BapodraA. Study of impurity carryover and impurity profile in Febuxostat drug substance by LC-MS/MS technique.J. Pharm. Biomed. Anal.201156474975710.1016/j.jpba.2011.07.039 21840659
    [Google Scholar]
  6. AbdulM.A. AtulS. PrashantK. GauravU. FirozA. RishabhS. Validation of a statistically optimized stability indicating method for the estimation of febuxostat in a solid dosage form.EC Pharm. Sci2015130144
    [Google Scholar]
  7. MathrusriA.M. PavanS. KumarB. VenkateshB. ChitaranjanM. Development and Validation of a Stability- Indication RP-HPLC.Method Determination Febuxostat. J. Chroma. Sci.20135193193810.1093/chromsci/bms192
    [Google Scholar]
  8. DesariJ. PatelV. Development and validation of stability indicating LC-PDA method for simultaneous assessment of Febuxostat and Ketorolac Tromethamine in tablet dosage from.Asian J. Chem.201729697510.14233/ajchem.2017.20134
    [Google Scholar]
  9. SekharR. NallagatlaB. A stability indicating RP-HPLC method development for determination of Febuxostat in tablet dosage form.Carib. J. Sci. Tech.20131228237
    [Google Scholar]
  10. BalajiN. SayeedaS. Ultra-high performance liquid chromatographic determination of genotoxic impurities in Febuxostat drug substance and products. Asian.J. Phar. Clin. Res.2017101324330
    [Google Scholar]
  11. Chandra ReddyM. Chandra SekharK. Estimation of related substance of Febuxostat in bulk and tablet by RP-HPLC.Int. J. Pharm. Bio. Chem. Sci. (Camb.)201212110
    [Google Scholar]
  12. Fawzi, A High-performance thin-layer chromatographic methods for the determination of febuxostate and febuxostate/ diclofenac combination in human plasma.
  13. BishoyK. KennethM. WilliamsG. GrahamG. RossL.G. NorrisS.L. Stocker JaneE.C. KevinD.P. RichardO.D. Determination of febuxostate in human plasma by high performance liquid chromatography (HPLC) with fluorescence-detection.J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.20191126-1127121764
    [Google Scholar]
  14. XieaH. ZhijunW.B. DengaK. XuehuaJ. LingW. LvcG. An HPLC–MS/MS method for simultaneous determination of the active metabolites of febuxostate (67M-1, 67M-2 and 67M-4) in human plasma.J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.2014970243010.1016/j.jchromb.2014.08.038 25222745
    [Google Scholar]
  15. ICH Stability testing of new drug substance and products Q1A (R2)International conference on harmonization, Food and drug administration, USA2003
    [Google Scholar]
  16. ICH Validation of analytical procedure Q2 (R1)International conference on harmonization, Food and drug administration, USA1995
    [Google Scholar]
/content/journals/ccchem/10.2174/2666001601666210427114547
Loading
/content/journals/ccchem/10.2174/2666001601666210427114547
Loading

Data & Media loading...


  • Article Type:
    Research Article
Keyword(s): degradation; Febuxostat; linearity; precise; RP-HPLC; stability indicating
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test